Trixeo Aerosphere is an inhalation treatment for chronic obstructive pulmonary disease (COPD) and contains a triple combination of budesonide, formoterol, and glycopyrronium. The treatment has previously been approved in a large number of countries for COPD using the propellant HFA-134a.
When HFA-134a was introduced, it served as an alternative to...
AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential
AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce environmental impact by 99.9%.
Astra Zeneca, Cambridge. Photo: Astra Zeneca
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration